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Background: We aimed to compare chest low-dose computed tomography (LDCT) with chest
radiography (CXR) in the assessment of febrile acute myeloid leukaemia neutropenic patients.
Methods: A prospective non-randomized study was carried out between 30 May, 2003 and 3 June,
2004 in consecutive neutropenic patientswho required imaging of the thorax andwere treated for
acutemyeloid leukaemia. Each patient had a baseline 2-view chest radiograph followed by LDCT.
Both the CXR and the LDCT studies were blindly and independently reviewed by two chest
radiologists.
Results: Forty patientswere enrolled: 24male and 16 female,mean age 53.5 years (range 18e83)
and an average neutrophil count of 0.78  109/L. Patients had CXR within a mean of 40 min from
the LDCT. Overall, 31 (77.5%) of 40 CXR were abnormal, whereas LDCT detected abnormalities in
38 (95%) of 40 patients. LDCT demonstrated three times the number of lung nodules as CXR and
twice as many ground-glass opacities. Lung consolidation was detected similarly using both tech-
niques, but LDCT demonstrated more extensive and multi-focal consolidation. The majority of
nodules detected only on LDCT were subcentimetre in diameter. The additional information
provided by LDCT led to an alteration in the clinical management of 11 (27.5%) of 40 patients.
Conclusion: LDCT is a useful tool in the initial investigation of suspected pulmonary complication
in neutropenic patients. This is supportedby theadditional information it provides to theCXRwith
reduced radiation when compared to conventional CT.
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Chest LDCT vs. CXR in AML patients 601Introduction The purpose of our study was to compare thoracic LDCTTable 1 Inter-reader concordance for CXR and low-dose
CT.
CXR NZ40 (%) LDCT NZ40 (%)
Normal Abnormal Normal Abnormal
Reader 1 9 (22.5) 31 (77.5)* 2 (5) 38 (95) NS
Reader 2 14 (35) 26 (65)* 2 (5) 38 (95) NS
Concordance 5 (12.5) 25 (62.5)* 2 (5) 38 (95) NS
Consensus read 9 (22.5) 31 (77.5)* 2 (5) 38 (95) NS
* p < 0.01, NS, not significant.Patients with haematological malignancies are at increased
risk of potentially fatal infections as a consequence of
treatment-induced neutropenia.1 Respiratory complica-
tions occur in up to 70% of allogeneic haematopoietic stem
cell transplantation (SCT) patients, and are a leading cause
of morbidity and mortality in this group of patients with
mortality estimated at 38e92%.2e6 Prompt identification
and treatment is critical to achieve a good outcome.
However, establishing a diagnosis is challenging as, in the
presence of modest immune response, many of the tradi-
tional chest radiograph findings of early infectious and non-
infectious processes are subtle, non-specific and may not
be recognized.2,7,8 Currently, the common approach to the
immunocompromised patient with fever or respiratory
symptoms is to assess pulmonary involvement by chest
radiography (CXR), start empirical broad-spectrum antibi-
otics early, and add antifungal agents if fever or symptoms
persist, while awaiting the results of non-invasive tests and
commonly assessing with repeated CXR. Empiric treatment
with broad-spectrum antibiotics is initiated prior to
microbiologic confirmation as the results are not immedi-
ately available and may only be positive in 10e40% of
cases.1 In addition, invasive procedures such as bronchos-
copy, percutaneous or open lung biopsy are performed in
order to obtain specimens if pulmonary changes are iden-
tified on CXR.9e12
However, in the face of severe immunodeficiency, the
systemic and pulmonary inflammatory response to infec-
tious and non-infectious processes may be poor and occa-
sionally virtually absent. Thus, due to its low sensitivity,
plain CXR may be normal or show only minimal non-specific
abnormalities.13 Accordingly, the use of plain CXR for
evaluation of fever or respiratory symptoms could delay
further diagnostic procedures and targeted treatment.14 It
had been shown previously that delaying treatment in
severely immunocompromised patients could be potentially
fatal.15 Due to its greater sensitivity, chest computed
tomography (CT) scanning has been proposed to replace the
plain CXR in the primary evaluation of immunocompromised
patients. Previous studies demonstrated that CT of the
thorax is superior to CXR in the management of pulmonary
complications in patients with AIDS16 and in patients with
haematological malignancies, but is performed at a signifi-
cantly increased radiation dose to the patient. High-reso-
lution CT (HRCT) is performed at a lower radiation exposure
and has been shown to be useful in the assessment of
diffuse lung disease in immunocompromised patients.17
However, the technique is limited in the assessment of
focal lung abnormalities. Due to the high mortality rate
which is associated with pulmonary complication in this
group of immunocompromised patients and the repeated
use of imaging assessment in each event, it is important to
find a technique that combines low radiation dose with high
sensitivity for focal lung processes. In recent years the use
of low-dose CT (LDCT) of the thorax has become a prom-
ising alternative to the CXR and HRCT. It combines signifi-
cant radiation dose reduction with a volumetric assessment
of the thorax, and has been successfully used in the
paediatric AIDS population.18to CXR in the initial assessment of ill neutropenic patients
with acute myeloid leukaemia (AML). Our hypothesis was
that LDCT significantly increases the number of abnormal
pulmonary studies in comparison to CXR.
Material and methods
A prospective, non-randomized study was performed in
a single-site, tertiary care oncology centre from30May, 2003
to 3 June, 2004. All neutropenic patients treated for AML and
requiring thoracic imaging to exclude pulmonary infection or
complications were eligible for the trial. Each enrolled
patient had a departmental 2-view digital (DR) chest radio-
graph followed by a non-enhanced thoracic LDCT performed
in an adjacent imaging suite. The LDCT studies were per-
formed on a 4-row multi-detector CT unit (Lightspeed,
General Electric Medical Systems, Milwaukee, WI), using the
following parameters: 120 kV, 50 mA, gantry rotation 0.8 s,
table speed 15 mm/s and beam collimation of 5 mm. Images
were reconstructed at 5-mm intervals with a 50% overlap
using high and low spatial frequency reconstruction filters.
Soft copy evaluation was performed on a stand-alone PACS
workstation using standardmediastinal (W 350 L 50) and lung
(W 1500 L 600) window settings. Two experienced staff
thoracic radiologists (N.P., T.B.C.) who were aware of the
clinical diagnosis performed an independent evaluation of
the studies in random order, blinded to the results of the
alternative study. Each examination was assessed for
radiological stigmata of infection, namely areas of consoli-
dation, ground-glass opacity (GGO) and lung nodules.16e18
Consolidation was defined as an area of increased lung
opacification with obscuration of the lung vasculature, as
distinct from GGO in which the increased lung opacity does
not obscure the underlying vessels. A lung nodule was
defined as a focal opacity measuring 3e30 mm in diameter
on standard lung window settings (W 1500, L 600). The
studies were also reviewed for features suggestive of an
alternative explanation for the patients’ clinical deteriora-
tion in particular, the presence of pleural or pericardial
effusions, and interlobular septal thickening to suggest
cardiac failure or fluid overload. Discrepancies were settled
by consensus. The examination was well tolerated and
successfully performed on all patients using a single breath
hold of 8e12 s.
The radiological findings were verbally communicated to
the supervising physician at the time of imaging. A retro-
spective review of the patients’ hospital chart was made in
order to evaluate any alteration in patient management
Table 2 Comparison of CXR with LDCT in the detection of
radiological indicators of infection.
Modality Consolidation N (%) GGO N (%) Nodules N (%)
CXR 18 (45) 11 (27.5) 8 (20)
LDCT 17 (42.5) 21 (52.5) 23 (57.5)
Significance NS p < 0.01 p < 0.01
GGO, ground-glass opacity; Nodules, focal opacity 3e30 mm in
diameter.
602 D. Patsios et al.specifically attributable to the LDCT report and to docu-
ment the following parameters: signs of fever or sepsis, the
neutrophil count at the time of imaging, and the diagnostic
yield from blood and urine cultures and bronchoalveolar
lavage (BAL), if performed. The dose length product (DLP)
in milligrays was recorded from the CT console and used to
represent the radiation dose associated with the LDCT. This
measurement was compared with the DLP reading from
a recent (within 3 months) standard dose helical thoracic
CT (SDCT) performed on the same patient and equipment
using scan parameters that varied only in the milliampere
setting.
Statistical analysis
A sample size of 40 patients was used to provide the power
to detect a significant difference in the detection of
pulmonary changes between CXR and LDCT. To examine
whether or not LDCT differed from CXR in finding chest
diseases (consolidations, GGO, nodules and additional
abnormalities), the t-test was used. A p < 0.05 level of
statistical significance was used for all analyses.
Our Institutional Research Ethics Board approved this
study.
Results
Forty LDCTwere performed on 40 patients (24 males), mean
age 53.5 years (range 18e83). All patients had AML with
a mean neutrophil count of 0.78  109/L (range
0e6.2  109/L, normal reference 1.8e7.0  109/L) at the
time of imaging. Thirty-two (80%) of 40 patients wereFigure 1 (a,b) A normal chest radiograph does not show the subs
of the right upper lobe.pyrexial at the time of imaging; only 8 (20%) patients had
a positive microbiological culture, and these indicated
a respiratory tract infection as a cause of sepsis. Bron-
choalveolar lavage (BAL) was performed in 6 (15%) of 40
patients and was negative for infection in all cases. The
mean interval between the CXR and LDCTwas 40 min (range
2e332). The radiation dose for the LDCT was 106.3 mGy
(range 82.9e129.4 mGy). This represented a radiation dose
reduction of 83% in 11 of the 40 patients who had a recent
SDCT. All of the imaging studies were of diagnostic quality.
Inter-observer agreement in the detection of an
abnormal study was higher using LDCT, with complete
concordance in all patients compared to 25 (62.5%) of 40
chest radiographs (Table 1). There wereminor discrepancies
between observers using LDCT and these were due to inter-
pretation rather than detection of abnormalities: 2 patients
had isolated sub-3 mm lung opacities of doubtful clinical
significance. Using CXR, the inter-observer differences were
due to detection rather than interpretation with sub-
segmental atelectasis in 4 patients (10%), mild interlobular
septal thickening (1 patient), subsegmental GGO (1 patient)
and an isolated sub-5 mm pulmonary nodule (1 patient). The
two patients with normal LDCT studies had normal chest
radiographs.
Overall, 31 (77.5%) of 40 chest radiographs were
abnormal, whereas LDCT detected significant abnormalities
in 38 (95%) of 40 patients (p < 0.01). The use of LDCT was
associated with a significant increase in the ability to iden-
tify lung nodules and ground-glass opacities. Demonstrating
three times the number of lung nodules as CXR (LDCT 57.5%,
CXR 20%, p < 0.01) and twice as many ground-glass opacities
(LDCT 52.5%, CXR 27.5%, p < 0.01) (Table 2 and Figs. 1a,b,
Fig. 2). Lung consolidation was detected similarly using both
techniques (LDCT 42.5, CXR 45%, not significant) but LDCT
demonstrated more extensive and multi-focal consolidation
(Fig. 3a,b). The majority of nodules detected only on LDCT
were subcentimetre in diameter; approximately 44% of
these were distributed in a centrilobular pattern (Table 3
and Fig. 4). Of the remaining nodules, the radiological
appearance was suggestive of fungal infection. The addi-
tional information provided by LDCT led to an alteration in
the clinical management of 11 (27.5%) of 40 patients. In 10
(94%) of 11 patients this was due to a change in antibiotic
coverage to include previously unsuspected fungal disease.egmental area of ground-glass opacity in the posterior segment
Figure 2 (a, b) Normal frontal chest radiograph, subtle retrosternal area of consolidation on the lateral radiograph and a focal
area of consolidation and ground-glass opacity on the LDCT in the anterior segment of the left upper lobe.
Chest LDCT vs. CXR in AML patients 603The remaining patient had an earlier discharge based on
a normal LDCT scan.
Table 4 illustrates additional radiological features that
were indicative of underlying cardiopulmonary disease.Discussion
Patients with neutropenic sepsis have a mortality rate
approaching 60%.19 The diagnosis of pulmonary infection is
often difficult due to a lack of localizing clinical signs and
symptoms. Approximately 50e60% of neutropenic patients
with fever do not have microbiological evidence of infec-
tion20 but are treated with broad-spectrum antibiotics. The
empirical use of these drugs has resulted in a shift of caus-
ative agents from Gram-negative bacilli to more indolent,
Gram-positive bacterial and fungal pathogens.21,22 The
mortality rate in cases of invasive fungal disease approaches
90%23,24 and as empirical antifungal therapy is not routinely
prescribed, a high index of clinical suspicion needs to be
maintained in the at-risk patient population.25e28
With a significantly higher radiation dose, CTof the thorax
is superior to CXR in identifying patients with thoracic
disease and in the differential diagnosis of pulmonary
complications in immunocompromised patients.16 The
importance of dose reduction in imaging procedures has
been highlighted with higher risks of radiation-induced fatal
malignancies in the paediatric and adult population.30e32
The radiation dose is reduced with HRCT of the chest, whichFigure 3 (a, b) The chest radiograph shows right lower zone no
shows septal thickening, ground-glass airspace opacification and
limited portion of the right middle lobe included on the section.has been shown to be helpful in the assessment of acute
diffuse lung disease in immunocompromised patients.17,32
However, HRCTsamples 10% of the lung and could potentially
miss significant early small volume disease. LDCT with thin
beam collimation has been successfully applied in the
management of chest disease in AIDS patients.18 With
technological advances in multi-detector CT units,
a substantial dose reduction is feasible without compro-
mising the quality of the examination.31e36
In this study, the radiological indicators of pulmonary
infection were areas of consolidation, GGO and lung
nodules. Although the radiological sign of GGO is non-
specific,37 in the clinical setting of neutropenic sepsis in
leukaemic patients the finding favours an infective
process.17 Other considerations would include chemo-
therapy-induced lung disease, leukaemic infiltration (which
is rarely demonstrated radiologically) and early pulmonary
oedema likely to be related to the patients’ treatment. In
this study, LDCT demonstrated twice the number of GGO as
CXR and revealed more extensive, multi-focal disease. The
presence of multiple non-calcified pulmonary nodules gains
significance in the immunocompromised host and are most
commonly caused by infections. Considering the prognostic
implications of missing fungal disease, the detection of non-
calcified lung nodules in this at-risk patient population is
treated as suspicious of fungal disease. In this study, LDCT
demonstrated three times the number of lung nodules than
CXR. An exception to this is the detection of centrilobular
nodules with a ‘‘tree-in-bud’’ configuration. This patterndular opacities and minor limited septal thickening. The LDCT
patchy areas of consolidation in the right lower lobe and the
Table 3 Distribution of disease detected with LDCT.
Abnormality Distribution N %
Consolidation 17 42.5
Lobar 2 5
Segmental/subsegmental 15 37.5
Ground-glass opacity 21 52.5
Lobar 10 25
Segmental/subsegmental 11 27.5
Nodules 23 57.5
Random 13 32.5
Centrilobular 10 25
Table 4 Frequency of additional thoracic abnormalities
detected.
Feature LDCT CXR Significance
N % N %
Pleural effusion 19 47.5 18 45 NS
Diffuse interlobular
septal thickening
12 30 14 35 NS
Pericardial effusion 11 27.5 0 0 p < 0.001
Atelectasis 15 37.5 2 5 p < 0.01
Pulmonary artery
enlargement (>28 mm)
6 15 0 0 p < 0.001
Lung disease
(emphysema, fibrosis)
3 7.5 0 0 p < 0.01
604 D. Patsios et al.was detected in a quarter of the patients, raising concern for
aerogenous spread of infection and mucoid impaction of
distal airways. This pattern of disease was not accurately
demonstrated by CXR.
Overall, in this study LDCT provided an increase in
diagnostic yield in 17.5% of patients with neutropenic
sepsis, prompting an alteration in the patient’s clinical
management in 27.5% of patients. The major impact of
LDCTwas an alteration in the antibiotic coverage to include
clinically occult but radiologically suspected fungal
disease. We believe that this is a significant contribution in
the utility of LDCT as a tool in the investigation of neu-
tropenic patients with suspected pulmonary infection.
There are some limitations to this study. Only 20% of
patients had confirmatory microbiological evidence for
infection and a smaller percentage had diagnostic bron-
choalveolar lavage. This is in keeping with other published
studies in which the rates of microbiological confirmation
are 10e40%.1 Isolation of causative organism is often diffi-
cult on presentation, and empirical treatment is often
based on the clinical evaluation together with the radio-
logical pattern of disease.17,29 No patients were felt to be
suitable for a thoracoscopic video-assisted biopsy or
percutaneous fine-needle aspiration biopsy.Figure 4 Normal CXR in a febrile neutropenic patient where
the LDCT shows cluster of centrilobular nodules consistent with
mucoid impaction of distal small airways.In conclusion, LDCT is a useful imaging tool in the initial
investigation of neutropenic patients with suspected
pulmonary infection. It is a more sensitive technique than
CXR in the demonstration of subtle but important radio-
logical features suggestive of cardiopulmonary compro-
mise. Unlike HRCT, the technique allows assessment of the
entire lung and the radiation dose is 17% that of a standard-
dose CT of the thorax and approximately five times that of
a 2-view standard CXR. In these immunocompromised
patients, identifying early pulmonary changes may alter the
clinical approach. The patient may undergo early diagnos-
tics procedures, and the physician may apply early antibi-
otics therapy, all of these early interventions having the
potential to modify the outcome.
Further caseecontrol studies are needed to assess
whether the increased sensitivity of the LDCT in the
immunocompromised patients is translating into real
change in management, treatment, morbidity or mortality.
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